Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive and irreversible decrease in lung function, in which the walls of the air sacs (called alveoli) become thickened and damaged. Common symptoms count fatigue, sticky nails shortness of breath, and dry cough. Some other symptoms are joint pain, muscle pain, and weight loss. Further complications count pneumonia, pulmonary embolism, heart failure, and high blood pressure.
Some of the key factors that can cause lung damage count charcoal dust, hard metal dust, asbestos fibres, environmental factors such as silica dust, Epstein-Barr virus, herpes zoster virus, and gastrointestinal acid reflux. Treatments for idiopathic pulmonary fibrosis (IPF) count lung transplantation, symptom management, pulmonary rehabilitation, and oxygen therapy. Prescribed antifibrotic drugs are nintendetinib and pirfenidone.
Request a FREE sample copy – Idiopathic Pulmonary Fibrosis Treatment market report click here: https://www.coherentmarketinsights.com/insight/request-sample/2466
The growing geriatric population is likely to significantly increase the size of the global idiopathic pulmonary fibrosis treatment market. According to a 2015 report by the National Institutes of Health (NIH), symptoms of IPF appear in the U.S. between the ages of 50 and 70. Furthermore, the increasing prevalence of idiopathic pulmonary fibrosis is also likely to drive market growth. The incidence of idiopathic pulmonary fibrosis is 13-20 per 100,000 people worldwide, according to NIH 2015 estimates.
Smoking is thought to be another reason of idiopathic pulmonary fibrosis. According to the Centres for Disease Control and Prevention (CDCP), in 2017, there were approximately 1 billion smokers worldwide. The availability of antifibrotic drugs like Pirfenidone (Esbriet) and Nintedanib (Ofev) IPF is likely to increase the revenue of the global idiopathic pulmonary fibrosis treatment market significantly. Esbriet’s worldwide sales in 2016 were US $ 753 million, according to F. Hoffmann-La Roche AG’s annual report.
Lack of availability and awareness of appropriate treatment is likely to obstruct the growth of idiopathic pulmonary fibrosis market. 54% of patients in Europe do not receive any antifibrotic treatment, according to a 2017 report by the National Center for Biotechnology Information (NCBI).
Furthermore, the misdiagnosis of IPF is likely to hamper the size of the global idiopathic pulmonary fibrosis treatment market. For example, according to Multidisciplinary Respiratory Medicines (MRM), about 50% of IPF cases misdiagnosed for other lung diseases in 2012 in the U.S. High costs linked with the treatment of idiopathic pulmonary fibrosis are also likely to obstruct growth of market. For example, the treatment for idiopathic pulmonary fibrosis costs US $ 100,000 annually, according to data published in the American Journal of Managed Care (AJMC) in 2014.
Due to the increasing incidence of idiopathic pulmonary fibrosis, North America dominated the idiopathic pulmonary fibrosis market in 2017. According to the NIH, 2015, about 100,000 people are affected by IPF and the U.S. About 30,000 to 40,000 new patients are diagnosed with the disease each year. Furthermore, the increasing approval of new drugs is likely to boost the global idiopathic pulmonary fibrosis treatment market in this area. For example, in 2015, Prometic Life Sciences Inc. To U.S. The first orphan drug for PBI-4050 was approved by the Food and Drug Administration (FDA). Similarly, in 2017, plasminogen (Riplasim) was introduced in the U.S. It was approved by the FDA as an orphan drug.
Europe was the second largest region in the global idiopathic pulmonary fibrosis treatment market in 2017, due to the growing coverage of IPF in the region. In 2015, for example, the European Pulmonary Fibrosis Patient Charter registered about 80,000 to 111,000 people suffering from IPF, and 30,000 to 35,000 patients are diagnosed with the disease each year in Europe. The Asia-Pacific Idiopathic Pulmonary Fibrosis market is likely to grow significantly in the forecast period, as the number of people addicted to smoking in the region continues to grow. In 2017, for example, more than 30% of the world’s smokers were reported in Asia Pacific, according to World Bank figures.
𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐬? 𝐓𝐚𝐥𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2466
On the basis of Drug Type:
On the basis of Formulation:
- Soft Capsules
On the basis of Distribution Channel:
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
On the basis of Region:
- Middle East
- Asia Pacific
- Latin America
- North America
Key players performing in the global idiopathic pulmonary fibrosis treatment market are Prometic Life Sciences Inc., Promedior, Inc., Merck & Co., Inc., MediciNova, Inc., Galapagos NV, FibroGen, Inc., F. Hoffmann-La Roche, Cipla, Bristol-Myers Squibb Company, Boehringer Ingelheim, and Biogen.
Reasons to Buy this Idiopathic Pulmonary Fibrosis Treatment Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Idiopathic Pulmonary Fibrosis Treatment market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Idiopathic Pulmonary Fibrosis Treatment market
➡Leading company profiles reveal details of key Idiopathic Pulmonary Fibrosis Treatment market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Idiopathic Pulmonary Fibrosis Treatment market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Buy This Complete Business Report With Flat USD 2000 Off @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Idiopathic Pulmonary Fibrosis Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Idiopathic Pulmonary Fibrosis Treatment Industry Impact
Chapter 2 Global Idiopathic Pulmonary Fibrosis Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Idiopathic Pulmonary Fibrosis Treatment (Volume and Value) by Type
2.3 Global Idiopathic Pulmonary Fibrosis Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Idiopathic Pulmonary Fibrosis Treatment Sales, Consumption, Export, Import by Regions
Chapter 5 North America Idiopathic Pulmonary Fibrosis Treatment Market Analysis
Chapter 6 East Asia Idiopathic Pulmonary Fibrosis Treatment Market Analysis
Chapter 7 Europe Idiopathic Pulmonary Fibrosis Treatment Market Analysis
Chapter 8 South Asia Idiopathic Pulmonary Fibrosis Treatment Market Analysis
Chapter 9 Southeast Asia Idiopathic Pulmonary Fibrosis Treatment Market Analysis
Chapter 10 Middle East Idiopathic Pulmonary Fibrosis Treatment Market Analysis
Chapter 11 Africa Idiopathic Pulmonary Fibrosis Treatment Market Analysis
Chapter 12 Oceania Idiopathic Pulmonary Fibrosis Treatment Market Analysis
Chapter 13 South America Idiopathic Pulmonary Fibrosis Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Idiopathic Pulmonary Fibrosis Treatment Business
Chapter 15 Global Idiopathic Pulmonary Fibrosis Treatment Market Forecast (2021-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027